Clinical Trials on Parainfluenza in Colombia

Total 1 results

ModernaTX, Inc.

Active, not recruiting

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Human Metapneumovirus and Human Parainfluenza Infection

United States

3

Subscribe